New strategy aims to shield vulnerable transplant patients from dangerous virus
NCT ID NCT06812598
Summary
This study is testing if giving an antiviral drug called letermovir for a longer period (up to 24 weeks) can better prevent dangerous CMV infections in high-risk adults who have received a stem cell transplant from a donor. CMV is a common virus that can cause serious illness in people with weakened immune systems, like transplant patients. Researchers want to see if extending the standard preventive treatment reduces infections and improves safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology Department, The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.